Despite positive clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial opposition from PBMs. Such insurers are typically creating barriers to reimbursement, including significant expense requirements and approval processes that hinder user access. Analysts believe th